Loading clinical trials...

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia | Clinical Trials | Clareo Health

TERMINATEDPHASE2

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

NCT03063203•Washington University School of Medicine

View on ClinicalTrials.gov

Summary

In this study, the investigators seek to determine whether decitabine therapy can improve outcomes, specifically overall survival this selected subset of acute myeloid leukemia (AML) patients with the poorest prognosis based on refractoriness to induction treatment and high risk genetic mutations.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•TP53 mutant AML. The presence of a TP53 mutation should be determined by Genoptix (or institutional preferred equivalent assay). Detection of a TP53 mutation at the time of initial diagnosis is sufficient for enrollment at the time of relapsed/refractory disease. Detection of a TP53 mutation in either the peripheral blood or bone marrow is adequate for enrollment. Alternatively, patients who have not had TP53 mutation analysis performed, but who have \> 20% TP53 positive cells by immunohistochemistry detected on a bone marrow aspirate may also be enrolled,29 provided that mutation analysis is requested at the time of enrollment.
•Relapsed/refractory AML following 7+3 (or similar cytarabine containing induction chemotherapy for AML) disease detected by one of the following methods:
•* bone marrow blasts \> 5%, or
•* Hematologics flow cytometry assay (threshold \> 0.5%) (alternative equivalent assay may be substituted), or
•* Persistent cytogenetic abnormality (e.g. del5, del17p, etc), by FISH or conventional karotyping, or
•* Persistent TP53 mutation (at least 5 variant reads with at least 50x coverage) determined by Genoptix (or institutional preferred equivalent assay).
•Patients with \> 10% blasts on a day +14 bone marrow biopsy following 7+3 may either be enrolled or may be treated with a course of standard re-induction (e.g. 5+2 or similar) and then re-evaluated for response. Eligible patients will meet any of the above criteria on a subsequent biopsy.
•Bone marrow and organ function as defined below:
•* Peripheral white blood cell count \< 50,000/mcl (patients may receive hydroxyurea as necessary for cytoreduction),
•* Total bilirubin \< 1.5 x upper limit of normal,
+6 more criteria

Exclusion Criteria

•Prior treatment with either decitabine or azacitidine or an investigational agent
•Acute promyelocytic leukemia with PML-RARA or t(15;17).
•History of HIV, Hepatitis B, or Hepatitis C infection.
•Concurrent illness including, but not limited to, ongoing uncontrolled infection, symptomatic NYHA class 3 or 4 congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
•Radiation therapy within 14 days of enrollment.
•Chemotherapy administration in the 7 days preceding enrollment with the exception of hydroxyurea, which can be continued until Cycle 2. A washout period for oral tyrosine kinase inhibitors (e.g. Jakafi, etc) is not required, although tyrosine kinase inhibitors therapy must be discontinued prior to enrollment.
•Malignancies (other than AML) requiring active therapy or diagnosed within the last year, with the exception of non-melanoma skin cancer which can be treated or in situ malignancies (such as cervical, breast, prostate, etc.)
•Currently receiving any other investigational agents.
•Known central nervous system (CNS) leukemia or testicular involvement of leukemia
•A history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or other agents used in the study.
+1 more criteria

Locations (1)

Washington University School of Medicine

St Louis, Missouri, United States

Key Dates

Start Date

July 14, 2017

Primary Completion Date

February 13, 2021

Completion Date

March 16, 2022

Last Updated

June 2, 2022

Enrollment

ACTUAL participants

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia, Relapsed, Adult

Interventions

Decitabine

DRUG

Bone marrow biopsy/aspirate

PROCEDURE

Peripheral blood draw

PROCEDURE

Skin biopsy

PROCEDURE

Buccal swab

PROCEDURE

Phase I Study of HC-7366 for Acute Myeloid Leukemia

NCT06285890

Acute Myeloid Leukemia

View study

RECRUITINGPHASE2

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

NCT06220162

Acute Myeloid Leukemia

View study

RECRUITINGPHASE1/PHASE2

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

NCT04065399

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 2, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

Inclusion Criteria

Exclusion Criteria

Phase I Study of HC-7366 for Acute Myeloid Leukemia

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias